Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer

Acta Oncologica

Volumn 35, Issue 3, 1996, Pages 287-295

  Alfonso, Mauro ^a,b   Zeuthen, Jesper ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM2; GANGLIOSIDE GM3; HUMAN MONOCLONAL ANTIBODY;

B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CONFERENCE PAPER; DIAGNOSTIC VALUE; DRUG RESEARCH; HUMAN; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029973164     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609101643     Document Type: Conference Paper

References (67)

1. Pourtokalian J, Zwingelstein G, Doré J. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979; 94: 19-23.
2. Traylor TD, Hogan DL. Gangliosides from human cerebral astrocytomas. J Neurochem 1980; 34: 126-31.
3. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984; 44: 5914-20.
4. Gnewuch C, Jaques G, Havemann K, et al. Re-assessment of acidic glycosphingolipids in small cell lung cancer tissues and cell lines. Int J Cancer 1994; (Suppl 8): 125-6.
5. Lloyd KO. Tumor antigens known to be immunogenic in man. Ann NY Acad Sci USA 1993; 690: 50-7.
6. Cheung N, Saarinen U, Neely J, et al. Monoclonal antibodies to glycolipid antigen on human neuroblastoma cells. Cancer Res 1985; 45: 2642-9.
7. Natoli EJ, Livingston PO, Pukel CS, et al. A murine monoclonal antibody detecting N-acetyl and N-glycolyl GM2: Characterization of the cell surface reactivity. Cancer Res 1986; 46: 4116-20.
8. Yamamoto S, Yamamoto T, Saxton RE, et al. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3. J Natl Cancer Inst 1990; 82: 1757-60.
9. Watarai S, Onuma M, Yasuda T. Production of monoclonal antibodies specific for ganglioside GD3. J Biochem 1991; 110: 889-95.
10. Vangsted AJ, Clausen H, Kjeldsen TB, et al. Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. Cancer Res 1991; 51: 2879-84.
11. Nakamura K, Koike M, Shitara K, et al. Chimeric anti-ganglioside GM2 antibody with antitumor activity. Cancer Res 1994; 54: 1511-6.
12. Fredman P. Glycosphingolipid tumor antigens. Adv Lipid Res 1993; 25: 213-34.
13. Hakomori S. Aberrant glycosylation in tumors and tumor associated carbohydrate antigens. Adv Cancer Res 1989; 52: 257-331.
14. Tsuchida T, Ravindranath MH, Saxton RE, Irie RF. Gangliosides of human melanoma: Altered expression in vivo and in vitro. Cancer Res 1987; 47: 1278-81.
15. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterization by a mouse monoclonal antibody. J Exp Med 1982; 155: 1133-47.
16. Tai T, Paulson JC, Cahan LD, Irie RF. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci USA 1983; 80: 5392-6.
17. Cheung N-V, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985; 45: 2642-9.
18. Kotani M, Ozawa H, Kawashima I, et al. Generation of one set of monoclonal antibodies specific for a-pathway ganglioseries gangliosides. Biochem Biophys Acta 1992; 1117: 97-103.
19. Hamilton WB, Helling F, Lloyd KO, Livingslon PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromalography. Int J Cancer 1993; 53: 566-73.
20. Ruan S, Lloyd KO. Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: Relative glycosyltransferase levels determine ganglioside patterns. Cancer Res 1992; 52: 5725-31.
21. Wilkstrand CJ, Longee DC, McLendon RE, et al. Lactotetraose series ganglioside 3′,6′-isoLD11 in tumors of central nervous and other systems in vitro and in vivo. Cancer Res 1993; 53: 120-6.
22. Ravindranath M, Morton DL. Role of gangliosides in active immunotherapy with melanoma vaccine. Int Rev Immunol 1991; 7: 303-29.
23. Lloyd KO, Gordon CM, Thampoe IJ, DiBenedetto C. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition. Cancer Res 1992; 52: 4948-53.
24. Nores G, Dohi T, Taniguchi M, Hakomori S. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody and GM3-lactone as a possible immunogen: Requirements for tumor-associated antigen and immunogen. J Immunol 1987; 139: 3171-6.
25. Nudelman E, Hakomori S, Kannagi R, et al. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody 4.2. J Biol Chem 1982; 257: 12752-6.
26. Livingston PO, Jones M, Natoli E. Approaches to augmenting the immunogenicity of the ganglioside in mice: Purified GM2 is superior to whole cells. J Immunol 1987; 138: 1524-9.
27. Livingston PO, Ritter F, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989; 49: 7045-50.
28. 3 ganglioside: A phase-I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 84: 1242-6.
29. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986; 83: 8694-8.
30. Irie RF, Matsuki T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989; 1: 786-7.
31. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992; 52: 4342-7.
32. Livingston PO, Wong GYC, Adkuri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-44.
33. Tai T, Paulson JC, Cahan LD, et al. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985; 35: 607-12.
34. Portoukalian J, Carrel S, Dore JF, et al. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. Int J Cancer 1991; 49: 893-9.
35. Nakarai HP, Chandler PJ, Kano K, Morton DL, Irie RF. Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma. Int Arch Allergy Appl Immunol 1990; 91: 323-8.
36. Hirabayashi Y, Higashi H, Kato S, et al. Occurrence of tumor-associated ganglioside antigens with Hanganutziu/Deicher antigenic activity on human melanomas. Jpn J Cancer Res 1987; 78: 614-20.
37. Higashi H, Sasabe T, Fukui Y, et al. Detection of gangliosides as N-Glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 1988; 79: 952-6.
38. Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982; 79: 7629-33.
39. Irie RF, Sze LL, Saxton RE. Human antibody to OFA-1, a tumor antigen produced in vitro by EBV-transformed human lymphoblastoid cell line. Proc Natl Acad Sci USA 1982; 79: 5666-70.
40. Yamaguchi H, Furukawa K, Fortunato SR, et al. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 2416-20.
41. Furukawa K, Yamaguchi H, Oettgen HF, Old LJ, Lloyd KO. Analysis of the expression of N-glvcolylneuraminic acid-containing gangliosides in cells and tissues using two human monoclonal antibodies. J Biol Chem 1988; 263: 18507-12.
42. Furukawa K, Yamaguchi H, Oettgen HF, Old LJ, Lloyd KO. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with the corresponding mouse monoclonal antibodies. Cancer Res 1989; 49: 191-6.
43. Yamaguchi H, Furukawa K, Fortunato SR, et al. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. Proc Natl Acad Sci USA 1990; 87: 3333-7.
44. Usuba O, Fujii Y, Miyoshi I, Naiki M, Senda F. Establishment of a human monoclonal antibody to Hanganutziu-Deicher antigen as a tumor-associated carbohydrate antigen. Jpn J Cancer Res 1988; 79: 1340-8.
45. Lloyd KO. Humoral immune responses to tumor-associated carbohydrate antigens. Cancer Biol 1991; 2: 421-31.
46. Lloyd KO, Old LJ. Human monoclonal antibodies to glycolipids and other carbohydrate antigens: Dissection of the humoral immune response in cancer patients. Cancer Res 1989; 49: 3445-51.
47. Nozawa S, Narisawa S, Kojirna K, et al. Human monoclonal antibody (HMST-1) against lacto-series type 1 chain and expression of the chain in uterine endometrial cancers. Cancer Res 1989; 49: 6401-6.
48. Miyake M, Taki T, Kannagi R, Hitomi S. First establishment of a human monoclonal antibody directed to sulfated glycosphingolipids SM4s-Gal and SM4g, from a patient with lung cancer. Cancer Res 1992; 52: 2292-7.
49. Borrebaeck CAK, Danielsson L, Möller SA. Human monoclonal antibodies produced by primary in vitro immunized peripheral blood lymphocytes. Proc Natl Acad Sci USA 1988; 85: 3995-9.
50. Ohlin M, Broliden P-A, Danielsson L, et al. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping. Immunology 1989; 68: 325-31.
51. Ohlin M, Borrebaeck CAK. Production of human monoclonal antibodies. In: Masseyeff RF, Albert WHW, Staines NA, eds. Methods of immunological analysis. VCH Verlagsgesellschaft mbH 1993: 291-325.
52. Chin L-T, Malmborg A-C, Kristensson K, Hinkula J, Wahren B, Borrebaeck CAK. Mimicking the humoral immune response in vitro results in antigen-specific isotype switching supported by specific autologous T helper cells: Generation of HIV-1 neutralizing IgG monoclonal antibodies from naive donors. Eur J Immunol 1995; 25: 657-63.
53. Duenas M. Phage display and bacterial expression of antibody fragments (Dissertation). Lund, Sweden: Univ of Lund. 1995.
54. Chin L-T, Hinkula J, Levi M, Ohlin M, Wahren B, Borrebaeck CAK. Site-directed primary in vitro immunization: Production of HIV-1 neutralizing antibodies from sero-negative donors. Immunology 1994; 81: 428-34.
55. Gregoriadis G. Liposomes as immunological adjuvants: Approaches to immunopotentiation including ligand-targeting to macrophages. Res Immunol 1992; 143: 178-85.
56. Garcon NMJ, Six HR. Universal vaccine carrier: Liposomes that provide T-dependent help to weak antigens. J Immunol 1991; 146: 3697-702.
57. Van Rooijen N. Liposomes as an in vivo tool to study and manipulate macrophage function. Res Immunol 1992; 143: 177-8.
58. Alfonso M, Vázquez AM, Carr A, et al. T-cell independent B-cell response to self monosialogangliosides: Primary response monoclonal antibodies. Hybridoma 1995; 14: 209-16.
59. Gregoriadis G, Wang Z, Barenholz Y, et al. Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to overcome genetic restriction in mice and induce immunological memory. Immunology 1993; 80: 535-40.
60. Alfonso M, Lanne B, Ifversen P, et al. Antigen-specific primary immune response of human B lymphocytes after in vitro immunization with GM3 ganglioside. Human Antibodies and Hybridomas 1995; 6: 102-12.
61. O'Sullivan D, Arrhenius T, Sidney J, et al. On the interaction of promiscuous antigenic peptides with different DR alleles. J Immunol 1991; 147: 2663-9.
62. Vazquez AM, Alfonso M, Lanne B, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides which also recognizes sulfated glycolipids. Hybridoma 1995; 14: 551-6.
63. Shawler DL, Bartolomew RM, Smith LM, Dillman RD. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530-5.
64. Larrick JW, Bouria JM. Prospects for the therapeutic use of human monoclonal antibodies. J Biol Response Mod 1986; 5: 379-93.
65. van Kroonenburgh MJ, Pauwels EK. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Comm 1988; 9: 919-30.
66. 111Indium radiolabelled human IgM monoclonal antibodies: Preliminary studies. Radiology 1988; 167: 71-5.
67. Gomibuchi M, Saxton RE, Lake RR, Katano M, Irie RF. Radioimmunodetection of human melanoma tumor xenografts with human monoclonal antibodies. Int J Rad Appl Instr 1986; 13: 13-9.